Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Michels

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2023
Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian CancerFélix Blanc-Durand, Roseline Tang, Margaux Pommier, et al.
Journal for Immunotherapy of Cancer|June 30, 2022
Cancer cell-autonomous overactivation of PARP1 compromises immunosurveillance in non-small cell lung cancerPan Juncheng, Adrien Joseph, Antoine Lafarge, et al.
Bulletin Du Cancer|January 30, 2026
[French recommendations for clinical practice, Nice-Saint-Paul-de-Vence 2024-2025: Management of localized cervical cancer]Cyrus Chargari, Alejandra Martinez, Judith Michels, et al.
JCI Insight|May 5, 2022
Targeting genome integrity dysfunctions impedes metastatic potency in non-small cell lung cancer circulating tumor cell-derived explantsTala Tayoun, Vincent Faugeroux, Marianne Oulhen, et al.
Science Advances|September 18, 2024
NF-κB and TET2 promote macrophage reprogramming in hypoxia that overrides the immunosuppressive effects of the tumor microenvironmentCarlos de la Calle-Fabregat, Josep Calafell-Segura, Margaux Gardet, et al.
Clinical Kidney Journal|February 13, 2019
Renal toxicities associated with pembrolizumabHassan Izzedine, Alexis Mathian, Stephane Champiat, et al.
Journal for Immunotherapy of Cancer|July 2, 2024
Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancerJuan Francisco Grau Bejar, Elisa Yaniz Galende, Qinghe Zeng, et al.
Nature|August 8, 2017
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RASZhan Yao, Rona Yaeger, Vanessa S Rodrik-Outmezguine, et al.
Journal for Immunotherapy of Cancer|June 24, 2021
Metabolic features of cancer cells impact immunosurveillanceAdrien Joseph, Pan Juncheng, Michele Mondini, et al.
Cancer Research|April 5, 2013
Cisplatin resistance associated with PARP hyperactivationJudith Michels, Ilio Vitale, Lorenzo Galluzzi, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2023
Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian CancerFélix Blanc-Durand, Roseline Tang, Margaux Pommier, et al.
Journal for Immunotherapy of Cancer|June 30, 2022
Cancer cell-autonomous overactivation of PARP1 compromises immunosurveillance in non-small cell lung cancerPan Juncheng, Adrien Joseph, Antoine Lafarge, et al.
Bulletin Du Cancer|January 30, 2026
[French recommendations for clinical practice, Nice-Saint-Paul-de-Vence 2024-2025: Management of localized cervical cancer]Cyrus Chargari, Alejandra Martinez, Judith Michels, et al.
JCI Insight|May 5, 2022
Targeting genome integrity dysfunctions impedes metastatic potency in non-small cell lung cancer circulating tumor cell-derived explantsTala Tayoun, Vincent Faugeroux, Marianne Oulhen, et al.
Science Advances|September 18, 2024
NF-κB and TET2 promote macrophage reprogramming in hypoxia that overrides the immunosuppressive effects of the tumor microenvironmentCarlos de la Calle-Fabregat, Josep Calafell-Segura, Margaux Gardet, et al.
Clinical Kidney Journal|February 13, 2019
Renal toxicities associated with pembrolizumabHassan Izzedine, Alexis Mathian, Stephane Champiat, et al.
Journal for Immunotherapy of Cancer|July 2, 2024
Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancerJuan Francisco Grau Bejar, Elisa Yaniz Galende, Qinghe Zeng, et al.
Nature|August 8, 2017
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RASZhan Yao, Rona Yaeger, Vanessa S Rodrik-Outmezguine, et al.
Journal for Immunotherapy of Cancer|June 24, 2021
Metabolic features of cancer cells impact immunosurveillanceAdrien Joseph, Pan Juncheng, Michele Mondini, et al.
Cancer Research|April 5, 2013
Cisplatin resistance associated with PARP hyperactivationJudith Michels, Ilio Vitale, Lorenzo Galluzzi, et al.
Pageof 5